David Maasz | Chairman
BioFund Family Office
David Maasz is Co-Founder and Chair of BioFund, a mission-driven family office dedicated to curing and preventing cancer through a OneHealth approach. With 30+ years of entrepreneurial experience — including founding one of Central Europe’s first internet companies at age 19 — David brings a builder’s perspective to long-term biotech investment, shaped by the belief that the structural decisions made upstream of the science determine whether good biology ever becomes good medicine. BioFund’s portfolio spans biosimilar oncology biologics, a first-in-class multimodal protein remodeling the tumor microenvironment and making it accessible for different therapies, and the technology platforms and tools needed for both cure & prevention: from protein and cell engineering through human organoid screening to the UFP500° botanical processing platform. BioFund holds active academic and industry partnerships across Canada, the United States, and Europe.
'Curing and preventing cancer together. Because no one can do it alone'
Appearances:
Festival of Biologics Day 2 @ 11:50
What the Biology Can't Fix Good science doesn't automatically become good medicine. Some things have to be right before the biology even gets its chance
- li>
- The ClocksThe organizations that give research its own timeline systematically finish science that everyone else drops — and how separating the R clock from the D clock changes what survives.
- The SpeciesCompanion animal oncology is the most underused de-risking infrastructure in human biologics. The clinical data you need is already being generated. In a different clinic.
- The CapitalCapital structure is science strategy. The funding model you choose before the science runs determines what you’re allowed to attempt — and what you’ll be forced to abandon.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events